[1-[4-(1H-indazol-5-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-ylmethyl]piperidin-4-yl]carbamic acid tert-butyl ester | 1262787-36-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: [1-[4-(1H-indazol-5-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-ylmethyl]piperidin-4-yl]carbamic acid tert-butyl ester
• 英文别名: tert-butyl N-[1-[[4-(1H-indazol-5-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]methyl]piperidin-4-yl]carbamate
• CAS: 1262787-36-9
• 化学式: C₂₄H₃₀N₈O₂
• 分子量: 462.555
• InChiKey: AYFCQLGWFAVPCK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  124
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE
  申请人：Tsuboike Kazunari

  公开号：US20120149902A1

  公开（公告）日：2012-06-14

  Provided is a compound represented by the Formula (I) having a HER2 inhibitory action or a pharmacologically acceptable salt thereof, wherein T 1 is a phenyl group, an indazolyl group, or a benzofuryl group, n is an integer of 0 to 3, R 1 is a hydrogen atom, a halogen atom, a C 1-4 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, or a C 1-4 alkoxy group, m is an integer of 0 to 3, R 2 is a hydroxy group or a C 1-4 alkyl group optionally substituted with one or two C 1-4 alkoxy groups, and R 3 is a hydrogen atom, a C 1-4 alkyl group, or a C 2-6 alkynyl group.

  提供的是由式（I）表示的化合物，具有HER2抑制作用或其药理学上可接受的盐， 其中T 1 是苯基、吲唑基或苯并呋喃基，n为0至3的整数，R 1 是氢原子、卤原子、C 1-4 烷基、C 2-6 烯基、C 2-6 炔基或C 1-4 烷氧基，m为0至3的整数，R 2 是羟基或一个或两个C 1-4 烷氧基可选择地取代的C 1-4 烷基，R 3 是氢原子、C 1-4 烷基或C 2-6 炔基。
• SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20150218173A1

  公开（公告）日：2015-08-06

  The present invention relates to substituted indazol-pyrrolopyrimidine compounds of general formula I: in which R 1a , R 1b , R 1c , R 1d , R 2a are as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及通式I的取代的吲哚嘧啶-吡咯并嘧啶化合物：其中R1a，R1b，R1c，R1d，R2a如本文所述和定义，以及制备该化合物的方法，用于制备该化合物的中间化合物，包含该化合物的药物组合物和组合物，以及使用该化合物制造用于治疗或预防疾病的药物组合物，特别是用作唯一的活性成分或与其他活性成分组合使用，这些疾病特别是增生性和/或血管生成障碍。